These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 18362931)

  • 41. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma.
    Triozzi PL; Kim J; Aldrich W
    J Hematother Stem Cell Res; 2003 Jun; 12(3):279-87. PubMed ID: 12857369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of a tumour-specific CTL response by exosomes isolated from heat-treated malignant ascites of gastric cancer patients.
    Zhong H; Yang Y; Ma S; Xiu F; Cai Z; Zhao H; Du L
    Int J Hyperthermia; 2011; 27(6):604-11. PubMed ID: 21846196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells.
    Dai S; Zhou X; Wang B; Wang Q; Fu Y; Chen T; Wan T; Yu Y; Cao X
    J Mol Med (Berl); 2006 Dec; 84(12):1067-76. PubMed ID: 17016692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells.
    Alters SE; Gadea JR; Philip R
    Adv Exp Med Biol; 1997; 417():519-24. PubMed ID: 9286413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Granulocyte-macrophage colony-stimulating factor induces the differentiation of murine erythroleukaemia cells into dendritic cells.
    Cao X; Zhao Y; Yu Y; Wang Y; Zhang M; Zhang W; Wang J
    Immunology; 1998 Sep; 95(1):141-7. PubMed ID: 9767469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
    Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
    Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.
    Nair SK; Hull S; Coleman D; Gilboa E; Lyerly HK; Morse MA
    Int J Cancer; 1999 Jul; 82(1):121-4. PubMed ID: 10360830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
    Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
    Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Malignant effusions and immunogenic tumour-derived exosomes.
    Andre F; Schartz NE; Movassagh M; Flament C; Pautier P; Morice P; Pomel C; Lhomme C; Escudier B; Le Chevalier T; Tursz T; Amigorena S; Raposo G; Angevin E; Zitvogel L
    Lancet; 2002 Jul; 360(9329):295-305. PubMed ID: 12147373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
    Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
    AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
    Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
    Clin Immunol; 2001 Apr; 99(1):65-74. PubMed ID: 11286542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.
    Staff C; Mozaffari F; Haller BK; Wahren B; Liljefors M
    Vaccine; 2011 Sep; 29(39):6817-22. PubMed ID: 21195077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
    Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
    Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.